openPR Logo
Press release

Deadline on October 4th is coming up in Lawsuit for Investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP)

09-23-2022 02:32 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on October 4, 2022 in the lawsuit for certain investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP).

A Deadline is coming up on October 4, 2022 in the lawsuit for certain investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP).

A deadline is coming up on October 4, 2022 in the lawsuit filed for certain investors of Kiromic BioPharma, Inc. (NASDAQ: KRBP) over alleged securities laws violations by Kiromic BioPharma, Inc.

Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options and there are strict and short deadlines running. Deadline: October 4, 2022. NASDAQ: KRBP stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Kiromic BioPharma, Inc. (NASDAQ: KRBP) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the Offering Documents failed to disclose that the FDA had, prior to the filing of the Registration Statement and Prospectus, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

Those who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on October 4th is coming up in Lawsuit for Investors in Kiromic BioPharma, Inc. (NASDAQ: KRBP) here

News-ID: 2746594 • Views: 242

More Releases from Shareholders Foundation

Investigation announced for Investors in certain Waste Management, Inc. (NYSE: W …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Waste Management, Inc. (NYSE: WM) was announced. Investors in certain Waste Management, Inc. (NYSE: WM) Senior Notes, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in certain Waste Management, Inc. (NYSE: WM) Senior Notes follows a lawsuit filed
Lawsuit filed for Investors in shares of Barclays PLC (NYSE: BCS) Investor Alert …
An investor, who purchased shares of Barclays PLC (NYSE: BCS), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Barclays PLC in connection with certain allegedly false and misleading statements. Investors who purchased shares of Barclays PLC (NYSE: BCS), you have certain options and for certain investors are short and strict deadlines running. Deadline: November 22, 2022. NYSE: BCS investors should contact the Shareholders Foundation
Investigation announced for Investors in Torrid Holdings Inc (NYSE: CURV) over p …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Torrid Holdings Inc. Investors who purchased shares of Torrid Holdings Inc (NYSE: CURV) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Torrid Holdings Inc directors breached their fiduciary duties and caused damage to the company and its shareholders. City
Deadline on October 17th coming up in Lawsuit for Investors in Co-Diagnostics, I …
A deadline is coming up on October 17, 2022 in the lawsuit filed for certain investors of Co-Diagnostics, Inc. (NASDAQ: CODX). Investors who purchased shares of Co-Diagnostics, Inc. (NASDAQ: CODX) have certain options and there are strict and short deadlines running. Deadline: October 17, 2022. NASDAQ: CODX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the complaint filed in the U.S. District Court for

All 5 Releases


More Releases for Kiromic

Lawsuit filed for Investors in shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP)
An investor, who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP), filed a lawsuit over alleged violations of Federal Securities Laws by Kiromic BioPharma, Inc. in connection with certain allegedly false and misleading statements made between June 25, 2021 and August 13, 2021 and in connection with The Company's public offering closed on July 2, 2021 (the Offering). Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options
Dendritic Cell Cancer Vaccine Market- Global Industry Analysis, Size, Share, Gro …
The Dendritic Cell Cancer Vaccine Market research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Get a Free Sample Copy @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5994808 Segment by Type - CreaVax - Sipuleucel-T (Provenge) - Others Segment by Application - Pediatrics -
Investigation announced for Investors in shares of Kiromic BioPharma, Inc. (NASD …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiromic BioPharma, Inc. Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Kiromic BioPharma directors breached their fiduciary duties and caused damage to the company and its shareholders. Houston, TX
Investigation announced for Investors in shares of Kiromic BioPharma, Inc. (NASD …
An investigation was announced over potential securities laws violations by Kiromic BioPharma, Inc. in connection with certain financial statements. Investors who purchased shares of Kiromic BioPharma, Inc. (NASDAQ: KRBP), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Kiromic BioPharma, Inc. regarding its business, its prospects and its operations were
Dendritic Cell Cancer Vaccines Market Projected to Increase Faster During 2018-2 …
Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals. Download Sample Report @ https://www.alliedmarketresearch.com/request-toc-and-sample/2892 Increase in prevalence of cancer, improvement of
Innovative Report On Dendritic Cell Cancer Vaccine Market 2018 Global Analysis B …
Dendritic Cell Cancer Vaccine Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. Get FREE Sample Report Before Buying @ https://www.upmarketresearch.com/home/requested_sample/8629 UpMarketResearch offers a latest published report on “Global Dendritic Cell Cancer Vaccine Market Analysis and Forecast 2018-2023” delivering key insights and providing a competitive advantage